Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study

Vito Calabrese, Pierantonio Menna, Ombretta Annibali, Grazia Armento, Armando Carpino, Elisabetta Cerchiara, Carlo Greco, Francesco Marchesi, Paolo Spallarossa, Giuseppe Toglia, Giorgio Reggiardo, Giorgio Minotti

Research output: Contribution to journalArticle

Abstract

Asymptomatic diastolic dysfunction (DD) with preserved left ventricular ejection fraction (LVEF) is suspected to precede late cardiac events in cancer survivors treated by chemotherapy. We conducted the first multicenter study of early DD induced by chemotherapy. Patients who were candidates for standard dose chemotherapy were screened for the absence of cardiovascular risk factors, LVEF ≥50%, normal-for-age diastolic function at echocardiography (E/A ratio, E wave deceleration time; DT), normal levels of potential DD biomarkers like Nt-proBNP (≤125 pg/mL), and cardiac troponin I (cTnI, ≤0.05 ng/mL). Mitral Doppler (E/E’) was left at the investigator’s discretion. Chemotherapy-induced DD with preserved LVEF was diagnosed for patients showing LVEF ≥50% and any of the following: Nt-proBNP > 125 pg/mL, cTnI > 0.05 ng/mL, and out-of-range E/A and DT. Eighty patients (68 males, 12 females, median age 49 years) were evaluated at 1 week after chemotherapy (T1). Thirty-three protocol-defined diastolic events were observed (15 Nt-proBNP > 125 pg/mL, 14 grade I DD by E/A and DT, 4 cTnI > 0.05 ng/mL). The events occurred in 29 asymptomatic patients with LVEF ≥50% (36% incidence of DD with preserved LVEF). Interactions occurred between biomarkers and grade I DD. E/E’ abnormalities were not observed. Both anthracycline-based and nonanthracycline regimens induced DD. These findings show that biomarkers and echocardiography intercept early DD in otherwise asymptomatic low-risk cancer patients treated by standard dose chemotherapy. These findings therefore call for the adequate cardiac management of cancer patients.

Original languageEnglish
Pages (from-to)55-63
Number of pages9
JournalChemotherapy
DOIs
Publication statusAccepted/In press - Feb 9 2018

Fingerprint

Stroke Volume
Drug Therapy
Neoplasms
Biomarkers
Echocardiography
Heart Neoplasms
Troponin I
Deceleration
Anthracyclines
Multicenter Studies
Survivors
Research Personnel
Incidence

Keywords

  • Biomarkers
  • Cancer
  • Cardiotoxicity
  • Chemotherapy
  • Diastolic dysfunction
  • Echocardiography

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Calabrese, V., Menna, P., Annibali, O., Armento, G., Carpino, A., Cerchiara, E., ... Minotti, G. (Accepted/In press). Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study. Chemotherapy, 55-63. https://doi.org/10.1159/000486761

Early Diastolic Dysfunction after Cancer Chemotherapy : Primary Endpoint Results of a Multicenter Cardio-Oncology Study. / Calabrese, Vito; Menna, Pierantonio; Annibali, Ombretta; Armento, Grazia; Carpino, Armando; Cerchiara, Elisabetta; Greco, Carlo; Marchesi, Francesco; Spallarossa, Paolo; Toglia, Giuseppe; Reggiardo, Giorgio; Minotti, Giorgio.

In: Chemotherapy, 09.02.2018, p. 55-63.

Research output: Contribution to journalArticle

Calabrese, V, Menna, P, Annibali, O, Armento, G, Carpino, A, Cerchiara, E, Greco, C, Marchesi, F, Spallarossa, P, Toglia, G, Reggiardo, G & Minotti, G 2018, 'Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study', Chemotherapy, pp. 55-63. https://doi.org/10.1159/000486761
Calabrese, Vito ; Menna, Pierantonio ; Annibali, Ombretta ; Armento, Grazia ; Carpino, Armando ; Cerchiara, Elisabetta ; Greco, Carlo ; Marchesi, Francesco ; Spallarossa, Paolo ; Toglia, Giuseppe ; Reggiardo, Giorgio ; Minotti, Giorgio. / Early Diastolic Dysfunction after Cancer Chemotherapy : Primary Endpoint Results of a Multicenter Cardio-Oncology Study. In: Chemotherapy. 2018 ; pp. 55-63.
@article{c06057149cd7435d969b0a0c88c79f0c,
title = "Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study",
abstract = "Asymptomatic diastolic dysfunction (DD) with preserved left ventricular ejection fraction (LVEF) is suspected to precede late cardiac events in cancer survivors treated by chemotherapy. We conducted the first multicenter study of early DD induced by chemotherapy. Patients who were candidates for standard dose chemotherapy were screened for the absence of cardiovascular risk factors, LVEF ≥50{\%}, normal-for-age diastolic function at echocardiography (E/A ratio, E wave deceleration time; DT), normal levels of potential DD biomarkers like Nt-proBNP (≤125 pg/mL), and cardiac troponin I (cTnI, ≤0.05 ng/mL). Mitral Doppler (E/E’) was left at the investigator’s discretion. Chemotherapy-induced DD with preserved LVEF was diagnosed for patients showing LVEF ≥50{\%} and any of the following: Nt-proBNP > 125 pg/mL, cTnI > 0.05 ng/mL, and out-of-range E/A and DT. Eighty patients (68 males, 12 females, median age 49 years) were evaluated at 1 week after chemotherapy (T1). Thirty-three protocol-defined diastolic events were observed (15 Nt-proBNP > 125 pg/mL, 14 grade I DD by E/A and DT, 4 cTnI > 0.05 ng/mL). The events occurred in 29 asymptomatic patients with LVEF ≥50{\%} (36{\%} incidence of DD with preserved LVEF). Interactions occurred between biomarkers and grade I DD. E/E’ abnormalities were not observed. Both anthracycline-based and nonanthracycline regimens induced DD. These findings show that biomarkers and echocardiography intercept early DD in otherwise asymptomatic low-risk cancer patients treated by standard dose chemotherapy. These findings therefore call for the adequate cardiac management of cancer patients.",
keywords = "Biomarkers, Cancer, Cardiotoxicity, Chemotherapy, Diastolic dysfunction, Echocardiography",
author = "Vito Calabrese and Pierantonio Menna and Ombretta Annibali and Grazia Armento and Armando Carpino and Elisabetta Cerchiara and Carlo Greco and Francesco Marchesi and Paolo Spallarossa and Giuseppe Toglia and Giorgio Reggiardo and Giorgio Minotti",
year = "2018",
month = "2",
day = "9",
doi = "10.1159/000486761",
language = "English",
pages = "55--63",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Early Diastolic Dysfunction after Cancer Chemotherapy

T2 - Primary Endpoint Results of a Multicenter Cardio-Oncology Study

AU - Calabrese, Vito

AU - Menna, Pierantonio

AU - Annibali, Ombretta

AU - Armento, Grazia

AU - Carpino, Armando

AU - Cerchiara, Elisabetta

AU - Greco, Carlo

AU - Marchesi, Francesco

AU - Spallarossa, Paolo

AU - Toglia, Giuseppe

AU - Reggiardo, Giorgio

AU - Minotti, Giorgio

PY - 2018/2/9

Y1 - 2018/2/9

N2 - Asymptomatic diastolic dysfunction (DD) with preserved left ventricular ejection fraction (LVEF) is suspected to precede late cardiac events in cancer survivors treated by chemotherapy. We conducted the first multicenter study of early DD induced by chemotherapy. Patients who were candidates for standard dose chemotherapy were screened for the absence of cardiovascular risk factors, LVEF ≥50%, normal-for-age diastolic function at echocardiography (E/A ratio, E wave deceleration time; DT), normal levels of potential DD biomarkers like Nt-proBNP (≤125 pg/mL), and cardiac troponin I (cTnI, ≤0.05 ng/mL). Mitral Doppler (E/E’) was left at the investigator’s discretion. Chemotherapy-induced DD with preserved LVEF was diagnosed for patients showing LVEF ≥50% and any of the following: Nt-proBNP > 125 pg/mL, cTnI > 0.05 ng/mL, and out-of-range E/A and DT. Eighty patients (68 males, 12 females, median age 49 years) were evaluated at 1 week after chemotherapy (T1). Thirty-three protocol-defined diastolic events were observed (15 Nt-proBNP > 125 pg/mL, 14 grade I DD by E/A and DT, 4 cTnI > 0.05 ng/mL). The events occurred in 29 asymptomatic patients with LVEF ≥50% (36% incidence of DD with preserved LVEF). Interactions occurred between biomarkers and grade I DD. E/E’ abnormalities were not observed. Both anthracycline-based and nonanthracycline regimens induced DD. These findings show that biomarkers and echocardiography intercept early DD in otherwise asymptomatic low-risk cancer patients treated by standard dose chemotherapy. These findings therefore call for the adequate cardiac management of cancer patients.

AB - Asymptomatic diastolic dysfunction (DD) with preserved left ventricular ejection fraction (LVEF) is suspected to precede late cardiac events in cancer survivors treated by chemotherapy. We conducted the first multicenter study of early DD induced by chemotherapy. Patients who were candidates for standard dose chemotherapy were screened for the absence of cardiovascular risk factors, LVEF ≥50%, normal-for-age diastolic function at echocardiography (E/A ratio, E wave deceleration time; DT), normal levels of potential DD biomarkers like Nt-proBNP (≤125 pg/mL), and cardiac troponin I (cTnI, ≤0.05 ng/mL). Mitral Doppler (E/E’) was left at the investigator’s discretion. Chemotherapy-induced DD with preserved LVEF was diagnosed for patients showing LVEF ≥50% and any of the following: Nt-proBNP > 125 pg/mL, cTnI > 0.05 ng/mL, and out-of-range E/A and DT. Eighty patients (68 males, 12 females, median age 49 years) were evaluated at 1 week after chemotherapy (T1). Thirty-three protocol-defined diastolic events were observed (15 Nt-proBNP > 125 pg/mL, 14 grade I DD by E/A and DT, 4 cTnI > 0.05 ng/mL). The events occurred in 29 asymptomatic patients with LVEF ≥50% (36% incidence of DD with preserved LVEF). Interactions occurred between biomarkers and grade I DD. E/E’ abnormalities were not observed. Both anthracycline-based and nonanthracycline regimens induced DD. These findings show that biomarkers and echocardiography intercept early DD in otherwise asymptomatic low-risk cancer patients treated by standard dose chemotherapy. These findings therefore call for the adequate cardiac management of cancer patients.

KW - Biomarkers

KW - Cancer

KW - Cardiotoxicity

KW - Chemotherapy

KW - Diastolic dysfunction

KW - Echocardiography

UR - http://www.scopus.com/inward/record.url?scp=85042085917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042085917&partnerID=8YFLogxK

U2 - 10.1159/000486761

DO - 10.1159/000486761

M3 - Article

AN - SCOPUS:85042085917

SP - 55

EP - 63

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

ER -